---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-004296"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2022-06-10T23:59:59+00:00"
generated_at: "2026-06-25T02:59:51.065928+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Anika shareholders approve 250,000-share increase in 2017 incentive plan, reelect directors

## Summary
- Stockholders approved amendment increasing shares under 2017 Omnibus Plan from 4.6M to 4.85M; 10.1M in favor, 2.25M against.
- Cheryl R. Blanchard (Ph.D.) reelected as Class II director with 11.36M votes for, 1.11M against; Glenn R. Larsen (Ph.D.) with 11.98M for, 0.32M against.
- Ratification of Deloitte & Touche as auditor passed with 13.13M for, 0.08M against, 15.3K abstain; advisory say-on-pay passed with 12.15M for.
- Meeting turnout: 13.22M shares present (91.07% of voting power).

## SEC filing metadata
- accession: 0001171843-22-004296
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2022-06-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184322004296/0001171843-22-004296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184322004296/f8k_060822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-004296
- JSON: https://secwatch.observer/filing/0001171843-22-004296.json
- Plain text: https://secwatch.observer/filing/0001171843-22-004296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.